Gonadotropin levels at the start of ovarian stimulation predict normal fertilization after hCG re-trigger in GnRH antagonist cycles

Hiroya Kitasaka1 | Mikiko Tokoro1,2 | Masae Kojima1 | Noritaka Fukunaga1,2 | Yoshimasa Asada1,2

1Asada Ladies Clinic, Nagoya, Japan
2Asada Institute for Reproductive Medicine, Kasugai, Japan

Correspondence
Hiroya Kitasaka, Asada Ladies Clinic, Nagoya
Building 5F, 4-6-17 Meieki, Nakamura-ku, Nagoya, Aichi 450-0002, Japan.
Email: h_kitasaka@ivf-asada.jp

Abstract

Purpose: To assess the appropriateness of human chorionic gonadotropin (hCG) re-trigger in poor responders to gonadotropin-releasing hormone agonist (GnRHa) trigger in controlled ovarian stimulation (COS) cycles.

Methods: The 2251 cycles in 2251 patients triggered with GnRHa for oocyte stimulation, with or without requiring hCG re-trigger between 2013 and 2018, were retrospectively analyzed to compare gonadotropin levels at the start of COS and the rate of normal fertilization between the re-trigger and non–re-trigger group. Furthermore, patients in the re-trigger group were stratified by the rate of normal fertilization (good: ≥60% or poor: <60%) to compare patient demographics, hormone profiles, and clinical outcome between the subgroups.

Results: In the re-trigger group, FSH and LH levels at the start of COS were significantly lower in the good fertilization group than in the poor fertilization group (P < .01). Receiver operating characteristic curves identified cutoff values of the FSH and LH levels of 1.30 and 0.35 mIU/mL, respectively, for predicting ≥60% normal fertilization.

Conclusion: Gonadotropin levels at the start of COS are predictors of response to GnRHa trigger and hCG re-trigger necessity, and may serve as indicators to help clinicians appropriately choose hCG re-trigger rather than abandoning the cycles or continuing the first oocyte aspiration attempt.

Keywords
controlled ovarian stimulation, gonadotropin-releasing hormone antagonist protocol, gonadotropin-releasing hormone agonist trigger, luteinizing hormone surge, oocyte maturation
1 | INTRODUCTION

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of controlled ovarian stimulation (COS) protocols. The most common symptoms are decreased circulating blood volume, pleural/peritoneal fluid accumulation, and in serious cases, resulting in fatal cardiorespiratory impairment. The most possible pathogenesis of OHSS is the increased release of vascular endothelial growth factor (VEGF) by human chorionic gonadotropin (hCG) administered as an ovulation trigger in COS protocols, which induces capillary hyperpermeability. Although the reported incidence of OHSS in in vitro fertilization (IVF) cycles varies widely, mild OHSS and moderate-to-severe OHSS are expected to occur in 20%-33% and 3%-8%, respectively, of IVF cycles. In order to prevent OHSS, GnRH antagonist protocols using a GnRH agonist (GnRHa) as an ovulation trigger have been introduced in IVF cycles. GnRH antagonist protocols, as compared with conventional GnRHa long protocols, require a lower dose of gonadotropin medications and reduce the risk of serious OHSS. However, GnRHa trigger fails to achieve sufficient oocyte yields in some patients. Failures to retrieve adequate oocytes range from far fewer oocytes retrieved than expected from the number of mature follicles visible on the day of ovulation to empty follicle syndrome.

We have experienced such oocyte retrieval failures in patients undergoing GnRH antagonist protocols using GnRHa trigger. Some of the patients were rescued by re-triggering oocyte maturation with hCG, leading to successful oocyte retrieval and resulting in live births. However, the other patients were found to have morphologically abnormal cumulus-oocyte complexes (COCs) and lower rates of normal fertilization after hCG re-trigger. These experiences have led us to believe that hCG re-trigger may not be appropriate for all poor responders to GnRHa trigger.

This study retrospectively assessed the appropriateness of conducting hCG re-trigger based on fertilization outcomes and attempted to identify patient characteristics or hormone profiles, which might be predictive of normal fertilization after hCG re-trigger.

2 | MATERIALS AND METHODS

2.1 | Statement of ethics

All the procedures accorded with the ethical standards of the relevant committees on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments. The study design was approved by the ethics committee of the Institutional Review Board (IRB) of Asada Ladies Clinic. This is a retrospective study in patients who submitted informed consent for undergoing fertility treatment at our clinic. (IRB approval number: 2019-10).

2.2 | Patients

This study reviewed 2251 cycles of GnRH antagonist-based COS using GnRHa trigger for final oocyte maturation conducted in patients who received fertility treatment from 2013 to 2018 at our clinic. The patients who underwent oocyte retrieval more than once during the study period were not included. The opt-out method (potential participants were informed about research, information was available on our Web site, and patients were included unless they objected) approved by the IRB of Asada Ladies Clinic was used for this study to recruit the participants.

Among these, 36 cycles, in which adequate oocytes could not be collected at the first oocyte aspiration attempt probably because of suboptimal oocyte maturation, required hCG re-trigger; these cycles constituted the re-trigger group. The remaining 2215 cycles requiring no hCG re-trigger constituted the non-re-trigger group. Patients in the re-trigger group were matched for age with those in the non-re-trigger group to minimize age bias.

2.3 | Treatment

2.3.1 | Ovarian stimulation and frozen-thawed embryo transfer

Controlled ovarian stimulation was achieved with a flexible GnRH antagonist protocol. Patients received oral estrogen 2.0 mg (Julina tablets; Bayer Yakuhin) for 21 consecutive days from day 5 and oral progesterone 10.0 mg (Norlutent; Fuji Pharma) for 10 days from day 16 in the preceding cycle.

On day 3 of the menstrual cycle, gonadotropin treatment started. The gonadotropin medication(s) used for ovarian stimulation was chosen based on LH activity at the start of COS: Human menopausal gonadotropin (hMG) (HMG for injection; Ferring Pharmaceuticals; or HMG injection Teizo; Aska Pharmaceutical) was used alone if the LH level was <2 mIU/mL, or in combination with recombinant FSH (follitropin alfa [Gonal-F®; Merck]) if the LH level was ≥2 mIU/mL. Based on the facts that there is no report about LH surge occurring immediately after T1/2 and this protocol can reduce patient’s burden (clinic visit time and cost), when the lead follicular size reached ≥16 mm in diameter, a GnRH antagonist (ganirelix [Ganirest®; MSD] or cetorelix [Cetrotide®; 0.25 mg; Merck]) was initiated and continued every other day until the day final oocyte maturation was triggered. When three or more follicles reached a maximum diameter of 18-20 mm, final oocyte maturation was triggered with a GnRHa, either leuprolide acetate administered as a single injection of 1 mg [Lucrin®; AbbVie] or buserelin acetate administered as four intranasal doses of 300 μg per both nostrils, that is, 1200 μg in total [BUSERCUR®; Fuji Pharma].

The GnRHa trigger was scheduled for 21:00 to 22:00 and oocyte retrieval was conducted 36-40 hours after the GnRHa trigger.
On the day of oocyte retrieval, 5-10 follicles of ≥20 mm in diameter were initially aspirated from one or both ovaries. Patients with an oocyte recovery rate (the ratio of the number of collected oocytes to the number of aspirated follicles ≥20 mm in diameter) of >50% were deemed to require no re-trigger and subsequent aspirations were continued (non-re-trigger group). Patients with an oocyte recovery rate of ≤50%, and no or only a few oocytes were recovered, despite 5-10 follicles measuring ≥20 mm in diameter aspirated, the first oocyte stimulation with GnRHα trigger was presumed to have been suboptimal and the patient was given an hCG injection for re-triggering in the same cycle at the discretion of the clinicians (re-trigger group). The other follicles were kept in ovaries for the second oocyte retrieval. The second oocyte retrieval was scheduled 36 hours after administration of 5000 IU (or 3333 IU if the risk of OHSS was expected to be increased) of hCG (human chorionic gonadotropin for injection; Fuji Pharma).

Retrieved oocytes were fertilized using intracytoplasmic sperm injection (ICSI), and the embryos were cultured for up to 20 hours in a time-lapse imaging incubator (EmbryoScope; Vitrolife; or CCM-iBIS NEXT; Astec) that acquired images at 15-minute intervals. The appearance of two pronuclear (2PN) signified normal fertilization and that of ≥3 PN abnormal fertilization. All of the resultant embryos were cryopreserved at the pronuclear or blastocyst stage to prevent OHSS, until thawed for embryo transfer which was carried out in hormonally primed cycles using sequentially administered transdermal estradiol (Estrana®; Hisamitsu Pharmaceutical) and chlormadinone acetate (Lutoral®; Fuji Pharma). A clinical pregnancy was defined by the presence of a gestational sac by transvaginal ultrasound performed at approximately 4 weeks after embryo transfer.

2.4 | Patient characteristics and hormone profiles

The following patient characteristics and hormone profiles were compared between the re-trigger group and the non-re-trigger group: age, anti-Mullerian hormone (AMH) level, body mass index (BMI), total number of COS cycles, FSH and LH levels at the start of COS (day 3 of the menstrual cycle), total dose of GnRH antagonist required, total dose of gonadotropin required, serum estradiol (E2) and progesterone (P4) levels on the day of GnRHα trigger, and number of oocytes retrieved. We defined a 60% normal fertilization as a threshold for "good fertilization," based on previously reported rate of normal fertilization in ICSI cycles (68.6%-77.1%).21-23 The re-trigger group consisting of 36 patients was subdivided into a group of a ≥60% normal fertilization ("the good fertilization group") and a group of a <60% normal fertilization ("the poor fertilization group") to assess the following patient characteristics and hormone profiles: age, AMH level, FSH and LH levels at the start of COS (day 3 of the menstrual cycle), serum E2 and P4 levels on the day of GnRHα trigger, P4 level on the day of hCG re-trigger, and dose of hCG used for re-trigger. In addition, clinical outcomes (clinical pregnancy rate, clinical loss rate, and live birth rate) were compared between the good fertilization group and the poor fertilization group.

2.5 | Male partner's characteristics

To assess the effects of male partner's characteristics on fertilization outcomes, age, LH, FSH, total testosterone, semen volume, sperm concentration, and sperm motility in male partners were compared between the poor fertilization group and the good fertilization group.

2.6 | Statistical analyses

Before between-group comparisons, the Kolmogorov-Smirnov test or the Shapiro-Wilk test was conducted to assess data distribution in each group. For normally distributed data, F test was conducted and if the data showed homoscedasticity, t test was used to compare mean values between the groups. For data not normally distributed, the Mann-Whitney U test was used to compare median values between the groups. Rates in the groups were compared with the use of Fisher's exact test. The proportion of patients using each GnRHα medication was compared using chi-squared test. A free software “R” was used for all data analyses. A P-value of <.05 was considered statistically significant.

3 | RESULTS

3.1 | Comparisons of patient characteristics and hormone profiles between the re-trigger group and the non-re-trigger group

There were no significant differences between the re-trigger group and the non-re-trigger group in age, AMH level, BMI, the total number of COS cycles, the total dose of GnRH antagonist required, and serum E2 and P4 levels on the day of GnRHα trigger (Table 1). In the re-trigger group, the total dose of gonadotropin required was significantly higher, and FSH and LH levels at the start of COS were significantly lower than those in the non-re-trigger group (all P < .01). Since a decision to re-trigger was made by clinicians on the fact that no or only a few oocytes were retrieved, the number of oocytes retrieved in the re-trigger group (0.5 oocytes) was significantly lower than that in the non-re-trigger group (23 oocytes, P < .01).

The proportions of patients using each GnRHα medication in the non-re-trigger group were 75.3% with injectable leuprolide acetate and 24.7% with intranasal buserelin acetate, whereas those in the re-trigger group were 63.9% and 36.1%, respectively, with no difference in the choice of GnRHα medication between the groups (chi-squared test).
**TABLE 1** Characteristics and hormone profiles in patients treated with GnRHa trigger for final oocyte maturation (non–re-trigger group versus re-trigger group)

|                                | Non–re-trigger | Re-trigger | P-value* |
|--------------------------------|----------------|------------|----------|
| Number of patients             | 2215           | 36         | –        |
| N (number of cycles)           | 2215           | 36         | –        |
| Age at the start of COS (Y)    | 34 (31-37)     | 35 (32-38) | .098     |
| AMH (ng/mL)                    | 3.9 (2.85-5.6) | 3.65 (2.85-5.6) | .661     |
| BMI (kg/m²)                    | 20.3 (19.1-21.9) | 20.15 (18.875-22.4) | .789     |
| Total number of COS cycles     | 1 (1-2)        | 1 (1-2)    | .107     |
| FSH at the start of COS (day 3 of menstrual cycle) (mIU/mL) | 6.9 (5.8-8.1) | 2.6 (0.7-7.55) | <.01     |
| LH at the start of COS (day 3 of menstrual cycle) (mIU/mL) | 5.4 (4.0-7.1) | 1.4 (0-3.95) | <.01     |
| Total dose of GnRH antagonist required (mg) | 0.75 (0.75-1.00) | 0.75 (0.75-1.0625) | .438     |
| Total dose of gonadotropin required (IU) | 4200.0 (3375-4875) | 4837.5 (4162.5-5568.75) | <.01     |
| Proportion of patients using GnRHa injection (%) (leuprolide acetate injection) | 75.3 | 63.9 | .115     |
| Proportion of patients using GnRHa nasal preparation (%) (intranasal buserelin acetate) | 24.7 | 36.1 |          |
| Serum E2 on the day of GnRHa trigger (pg/mL) | 15 386 (12339-18955.5) | 13 615.5 (9492.25-18650.75) | .058     |
| Serum P4 on the day of GnRHa trigger (ng/mL) | 3.49 (2.41-4.88) | 3.475 (2.445-4.6975) | .854     |
| Serum P4 on the day of hCG re-trigger (ng/mL) | 23 (17-30) | 0.5 (0-1.25) | <.01     |

**Abbreviations:** AMH, anti-Mullerian hormone; COS, controlled ovarian stimulation; E2, estradiol; FSH, follicle-stimulating hormone; GnRHa, gonadotropin-releasing hormone agonist; LH, luteinizing hormone; P4, progesterone.

*For the proportions of patients using each GnRHa medication, comparisons were performed using chi-square test. Other values are shown as the median (interquartile ranges), and comparisons were performed using the Mann-Whitney U test.

**TABLE 2** Characteristics and hormone profiles in patients requiring hCG re-trigger, by the rate of normal fertilization (poor fertilization versus good fertilization group)

|                                | Poor fertilization (rate of normal fertilization <60%) | Good fertilization (rate of normal fertilization ≥ 60%) | P-value* |
|--------------------------------|-------------------------------------------------------|-------------------------------------------------------|----------|
| Number of patients             | 19                                                    | 17                                                    | –        |
| N (number of cycles)           | 19                                                    | 17                                                    | –        |
| Age at the start of COS (years) | 37 (32.5-38)                                          | 34 (32-36)                                           | .239     |
| AMH (ng/m)                     | 3.5 (2.45-4.2)                                        | 4.2 (3.1-7.2)                                        | .168     |
| FSH at the start of COS (day 3 of menstrual cycle) (mIU/mL) | 7.1 (2.85-8.25)                                       | 0.7 (0.4-1.1)                                        | <.01     |
| LH at the start of COS (day 3 of menstrual cycle) (mIU/mL) | 3.2 (2.1-5.4)                                         | 0 (0-0.3)                                            | <.01     |
| Total dose of GnRH antagonist required (mg) | 1 (0.75-1.25)                                         | 0.75 (0.5-1)                                         | <.01     |
| Total dose of gonadotropin required (IU) | 4875 (420-5475)                                      | 4800 (4050-5700)                                     | .937     |
| Proportion of patients using GnRHa injection (%) (leuprolide acetate injection) | 68.4 | 58.8 | .549     |
| Proportion of patients using GnRHa nasal preparation (%) (intranasal buserelin acetate) | 31.6 | 41.2 |          |
| Serum E2 on the day of GnRHa trigger (pg/mL) | 14 218 (8553-16228)                                  | 13 234 (11695-21325)                                | .271     |
| Serum P4 on the day of GnRHa trigger (ng/mL) | 4 (2.66-6.46)                                         | 3.23 (2.38-3.8)                                     | .11      |
| Serum P4 on the day of hCG re-trigger (ng/mL) | 12.39 (5.89-17.11)                                   | 3.3 (3.01-4.6)                                      | <.01     |
| Dose of hCG (IU)               | 3333 (3166.5-5000)                                   | 3333 (3333-5000)                                    | .842     |

**Abbreviations:** AMH, anti-Mullerian hormone; COS, controlled ovarian stimulation; E2, estradiol; FSH, follicle-stimulating hormone; GnRHa, gonadotropin-releasing hormone agonist; hCG, human chorionic gonadotropin; LH, luteinizing hormone; P4, progesterone.

*For the proportions of patients using each GnRHa medication, comparisons were performed using chi-square test. Other values are shown as the median (interquartile ranges) and comparisons were performed using the Mann-Whitney U test.
3.2 | Comparisons of patient characteristics and hormone profiles after hCG re-trigger between the good fertilization group and the poor fertilization group

There were no significant differences in age and AMH level between 17 patients in the good fertilization group and 19 patients in the poor fertilization group (Table 2). The LH and FSH levels at the start of COS (day 3 of the menstrual cycle) were significantly lower in the good fertilization group than in the poor fertilization group (P < .01). Total dose of gonadotropin required did not differ between the groups, but the good fertilization group required a significantly smaller dose of GnRH antagonist (P < .01). Serum P4 level on the day of hCG re-trigger was significantly lower in the good fertilization group than in the poor fertilization group (P < .01), whereas no significant differences were noted in serum P4 and E2 levels at GnRHa trigger between the groups.

The proportions of patients using each GnRHa medication in the poor fertilization group were 68.4% with injectable leuprolelin acetate and 31.6% with intranasal buserelin acetate, whereas those in the good fertilization group were 58.8% and 41.2%, respectively, with no difference in the choice of GnRHa medication between the groups (chi-squared test).

3.3 | Comparisons of clinical outcomes after hCG re-trigger between the good fertilization group and the poor fertilization group

There were no differences in the numbers of all oocytes and MII oocytes retrieved after hCG re-trigger between the good fertilization group and the poor fertilization group (Table 3). The good fertilization group had a significantly lower rate of abnormal fertilization, than did the poor fertilization group (P < .01). In the good fertilization group, all the patients (17 patients) underwent embryo transfer in or after the next cycle; however, in the poor fertilization group, 9 of the 19 patients (47.4%) had fertilization abnormalities and did not undergo embryo transfer. There were no significant differences in clinical pregnancy rate, clinical loss rate, and live birth rate between the groups.

3.4 | Hormone profiles and semen characteristics in male partners

The age, LH, FSH, and total testosterone levels in male partners did not significantly differ between the poor fertilization group and the good fertilization group (Table 4). Semen volume was significantly higher in the good fertilization group than in the poor fertilization group (P = .012), but no differences were noted in key factors for successful fertilization by ICSI, such as sperm concentration and sperm motility, between the groups.

3.5 | Morphology of COCs and denuded oocytes

The COCs in the good fertilization group were composed of swollen granulosa cells and multiple layers of cumulus cells (Figure 1A,B). The COCs in the poor fertilization group contained aggregated (Figure 1C) and black-colored (Figure 1D) granulosa cells. Denuded oocytes, after cumulus cells were removed, in the good fertilization group had no morphologically abnormal findings (Figure 2A-D). The poor fertilization group, on the other hand, had many denuded oocytes that were deemed morphologically abnormal, though some denuded oocytes were apparently normal (Figure 2c). The morphologically abnormal denuded

| TABLE 3 | Clinical outcomes in patients requiring hCG re-trigger, by the rate of normal fertilization (poor fertilization versus good fertilization group) |
|----------|-----------------------------------------------------------------------------------------------------------------------------------|
| N (number of cycles) | Poor fertilization (rate of normal fertilization <60%) | Good fertilization (rate of normal fertilization ≥ 60%) | P-value* |
| Number of total oocytes per retrieval after hCG re-trigger | 11 (7.5-19.5) | 20 (15-28) | .051 |
| Number of MII oocytes per retrieval after hCG re-trigger | 9 (6-16.5) | 15 (13-24) | .061 |
| Rate of normal fertilization (2PN) per MII oocyte (%) | 20 (10-30) | 80 (70-80) | <.01 |
| Rate of abnormal fertilization (≥3 PN) per MII oocyte (%) | 44.4 (20.8-55.6) | 3.8 (0-10.5) | .01 |
| Number of clinical pregnancies/number of patients with embryo transferred (Clinical pregnancy rate) | 4/10 (40.0%) | 10/17 (58.8%) | .44 |
| Number of clinical losses (rate) | 1 (33.3%) | 1 (14.3%) | .378 |
| Number of live births (rate) | 2 (66.7%) | 6 (85.7%) | 1.000 |

Abbreviations: hCG, human chorionic gonadotropin; MII, metaphase II.
*For the number of total and MII oocytes per retrieval and rates of normal and abnormal fertilization, the values are shown as median (interquartile ranges) and comparisons were performed using the Mann-Whitney U test. For clinical pregnancy rate, clinical loss rate, and live birth rate, the values are shown as mean ± SD and comparisons were performed using Fisher’s exact test.
oocytes observed in the poor fertilization group included oocytes having a large smooth endoplasmic reticulum (SER) in the center (Figure 2a), those with the black-colored zona pellucida and the perivitelline space containing abundant debris (Figure 2b), and those with rough cytoplasm, slightly oval zona pellucida, and fragmented polar bodies (Figure 2d).

### 3.6  Morphological change over time in fertilized oocytes

Time-lapse observation of fertilized oocytes in the good fertilization group revealed no morphological change or abnormality in the ooplasm (Figure 3A-C), except for poly-pronuclear embryos probably resulting from a failure of polar body extrusion occurring during oocyte maturation (Figure 3D). In the poor fertilization group, on the other hand, marked changes were seen in ooplasmic morphology. Figure 4A shows reverse cleavage, a phenomenon where oocyte cytoplasm was divided into two before pronuclear formation, and subsequently fused back to one. Figure 4B shows normal fertilization, despite debris being evident in the perivitelline space. Figure 4C shows abnormal fertilization resulting from an oocyte that appeared to be morphologically normal before fertilization but had “twisted” cytoplasm after fertilization. Figure 4D shows an oocyte with morphological abnormalities where direct cleavage occurred within several hours after fertilization and multiple distorted and shrunken blastomeres appeared 17.5 hours after fertilization. Thus, abnormal fertilizations occurred through different processes in the good fertilization group and the poor fertilization group.

### 3.7  Cutoff FSH and LH levels at the start of ovarian stimulation (day 3 of the menstrual cycle)

As above, the good fertilization group had significantly lower FSH and LH levels at the start of COS (both \( P < .01 \)). Based on the results,
relationships between FSH and LH levels at the start of COS, and
the rate of normal fertilization were assessed using receive oper-
ating characteristic (ROC) curves where sensitivity was plotted
against 1- specificity (Figure 5), and area under curves (AUCs) were
calculated to estimate optimal cutoffs of FSH and LH levels at the
start of COS to predict normal fertilization after re-trigger. The AUC
values were 0.87 (95% confidence interval [95% CI], 0.74-1.00) for
FSH level and 0.88 (95% CI, 0.79-1.00) for LH level. The ROC curves
also showed that an FSH level at the start of COS of 1.30 mIU/mL
had a sensitivity of 82.4% and specificity of 89.5% for predicting
≥60% normal fertilization, and that an LH level at the start of COS
of 0.35 mIU/mL had a sensitivity of 82.4% and specificity of 94.7%
for predicting ≥60% normal fertilization. Thus, LH level at the start
of COS was a more reliable predictor of normal fertilization after re-
trigger than FSH level at the start of COS.

4 | DISCUSSION

There have been sparse reports as to failures of final oocyte matu-
rature with GnRHa trigger, and the mechanism of the failures has
remained unclear. This is the first report focusing on the endocrine
environment at the start of COS and assessing the appropriateness
of conducting hCG re-trigger after failed final oocyte maturation
triggered with a GnRHa, based on fertilization outcome.

This study attempted to determine optimal cutoff FSH and LH
levels at the start of COS to identify patients requiring re-trigger
in advance. There have been several reports that the need for
re-trigger may be predictable from the endocrine environment
after GnRHa trigger. Kummer et al measured LH and P4 levels at
8 to 12 hours after GnRHa trigger and found that a low LH level
of <15 mIU/mL was associated with a suboptimal oocyte yield.
Similarly, Shapiro et al reported that a LH level of <12 mIU/mL at
12 hours after GnRHa trigger was associated with a dramatically
reduced oocyte yield.

However, measuring hormone levels on the day following
GnRHa trigger requires patients to revisit the clinic only for blood
sampling; this would increase the burden of patients and may be
undesirable in clinical practice. Furthermore, measuring hormone
levels on the day following GnRHa trigger in all patients is not
practical, in view of the low incidence of failed final oocyte mat-
uration with GnRHa trigger. On the other hand, assessing the en-
docrine environment at the start of COS, as we propose, may not
increase patient’s visit frequency.

FSH and LH levels at the start of COS in patients with good fertil-
ization after re-trigger were significantly lower than those in patients
with poor fertilization. Follicular development during COS is endo-
crinologically regulated by the hypothalamus-pituitary-ovary axis.
The hypothalamus secretes GnRH in pulses, and in response, the pi-
tuitary releases gonadotropins (FSH and LH). Low levels of FSH and
LH at the start of COS imply impaired pituitary function. In patients
with impaired pituitary function, exogenous FSH administered from
day 3 of a menstrual cycle may induce the secretion of E2, which “in
turn” inhibits the secretion of endogenous LH and FSH. If a GnRH
antagonist is administered under such an endocrine environment,
pituitary response would further reduce. In some patients with im-
paired pituitary function, administration of a GnRHa fails to cause
a flare-up of endogenous FSH and LH, resulting in a suboptimal LH
surge, poor oocyte maturity, and inadequate oocyte retrieval. Chang
et al reported that the probability of failed final oocyte maturation
with GnRHa trigger was twofold higher in patients with a baseline
LH level of 1-2 mIU/mL than in those with a higher LH level. Meyer
et al.\textsuperscript{15} found that patients with very low endogenous serum LH levels on the day of LH trigger are at increased risk for a suboptimal GnRHa trigger response, which is generally consistent with our finding. For patients with low FSH and LH levels at the start of COS, hCG trigger may be chosen for final oocyte ovulation. However, the expression of VEGF, which has already begun during ovary stimulation, is increased by hCG administration.\textsuperscript{7,25} VEGF is produced also in luteinized granulosa cells. Administration of hCG in the presence of numerous follicles increases the expression of VEGF,\textsuperscript{26,27} which, in turn, enhances vascular permeability, and thereby inducing OHSS. Thus, the hCG trigger as the first choice should be avoided; however, hCG injection may have to be used for re-triggering when the GnRHa trigger is not effective like the cases in this study. In such cases, strategies to prevent the development of OHSS may include lower dose of hCG or cabergoline administration. There are various reports regarding the effect of low dose of hCG,\textsuperscript{28,29} and Gunnala et al.\textsuperscript{30} reported that a single administration of low-dose hCG (3300 IU, similar to our study) can minimize the incidence of OHSS and facilitate oocyte maturity.\textsuperscript{30} Esinler et al.\textsuperscript{31} reported that cabergoline administration is a very effective way to reduce the risk of OHSS.\textsuperscript{31} According to the systematic review and meta-analysis by Leitao et al.\textsuperscript{32}, cabergoline reduces the occurrence of moderate-severe OHSS and is unlikely to have a negative impact on clinical pregnancy or on the number of retrieved oocytes. These treatment strategies cannot completely eliminate OHSS but can minimize the incidence of OHSS and control patients’ safety of hCG administration.

Although the incidence of abnormal fertilization after ICSI has been reported to be 2.4%-6.5%,\textsuperscript{33-36} the rate of abnormal fertilization after hCG re-trigger in patients with high FSH and LH levels at the start of COS was as high as 44.4% in our study. One possible explanation of the high rate of abnormal fertilization is the in vivo aging of oocytes, which is surmised from in vitro examinations. There have

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure3}
\caption{Time-lapse observation of morphological change over time in oocytes after ICSI in the good fertilization group. A-C, No morphological change or abnormality observed in the ooplasms. D, poly-pronuclear embryos occurred during oocyte maturation.}
\end{figure}
been many reports of oocyte aging. In mice, it was reported that abnormal fertilization increased by postovulatory oocyte aging and that in vitro aged postovulatory oocytes exhibited chromosomal misalignment and abnormal spindle formation, and failed to reach full-term development.38 It was also reported that human oocytes which had failed to fertilize after an 18-hour incubation with spermatozoa and had spent a further 6-8 hours in culture showed an increased incidence of spindle abnormalities and of the proliferation of ooplasmic microtubules,39 and chromosomes no longer aligned at the spindle equator but scattered all over the spindles.40,41 Zhang et al42 reported that the cumulus cells were separated from oocytes after a 24-hour in vitro incubation of COC. All these previous reports support in vivo oocyte aging.

As mentioned above, low gonadotropin levels imply impaired pituitary function. In patients with low gonadotropin levels, therefore, ovary stimulation with a GnRHa may fail to cause a flare-up of endogenous FSH and LH, which are affected by pituitary function, resulting in a suboptimal LH surge. For these patients, hCG re-trigger is effective. After hCG administration, oocytes begin to mature in good conditions, eventually leading to favorable fertilization rates. In patients with high gonadotropin levels, on the other hand, a GnRHa causes a flare-up of endogenous FSH and LH and induces an optimal

**FIGURE 4** Morphological change over time in oocytes after ICSI in the poor fertilization group. a, Reverse cleavage is shown (oocyte cytoplasm was divided into two before pronuclear formation and subsequently fused back to one); b, normal fertilization is shown, despite debris being evident in the perivitelline space; c, abnormal fertilization is shown resulting from an oocyte that appeared to be morphologically normal before fertilization but had the twisted cytoplasm after fertilization; and d, morphological abnormalities are shown (direct cleavage occurred within several hours after fertilization and multiple distorted and shrunken blastomeres appeared 17.5 h after fertilization.)
LH surge, in the presence of normal pituitary function. In the poor fertilization group, patients had high P4 levels at hCG re-trigger, suggestive of the occurrence of luteinization. This indicates that oocyte maturation had already begun with first trigger with a GnRHa. The necessity of re-trigger is judged solely based on difficulty to collect oocytes. During the 2 days, until the second oocyte retrieval was conducted, oocytes may have aged and overmatured in the body, leading to the dispersion of chromosomes on spindles and the increased incidence of abnormal fertilization. In patients with high gonadotropin levels at the start of COS, a certain number of oocytes may be collected by continuing the first oocyte aspiration attempt, without putting additional burdens of re-trigger and subsequent oocyte respiration on patients.

Failures of final oocyte maturation triggered with a GnRHa requiring hCG re-trigger occur with an extremely low frequency, and the endocrine environment can fluctuate even within the same patient. It can be therefore said that low FSH and LH levels at the start of COS are not direct causes of infertility but may be incidental symptoms. There have been many reports regarding suboptimal oocyte yield after GnRHa trigger43; however, most of the reports describe the possible association of hormone levels with oocyte yield after re-trigger, but not with fertilization or embryo development. Further investigation will be necessary focusing on the association of hormone levels with fertilization, embryo development, pregnancy, and delivery after re-trigger.

Currently, there are no established criteria or protocols to determine the appropriateness of hCG re-trigger. This study proposes that a FSH level of ≤1.30 mIU/mL and a LH level of ≤0.35 mIU/mL at the start of COS are expected to be optimal predictors of poor pituitary response to GnRHa trigger and need for hCG re-trigger. Conducting re-trigger solely based on the fact that adequate oocytes were not retrieved by the first oocyte aspiration attempt may cause oocyte overmature resulting in the increased incidence of abnormal fertilization. Low levels of FSH and LH at the start of COS, in combination with the fact that adequate number of oocytes were not retrieved, would warrant the conduct of hCG re-trigger to collect normally fertilized oocytes. Gonadotropin levels, that is, a FSH level of ≤1.30 mIU/mL and a LH level of ≤0.35 mIU/mL at the start of COS are predictors of poor pituitary response to GnRHa trigger and need of hCG re-trigger, and may serve as indicators to help clinicians appropriately choose hCG re-trigger rather than abandoning the cycles or continuing the first oocyte aspiration attempt.

ACKNOWLEDGMENTS

The authors would like to thank Tomokuni Yoshimura, Emiko Asano, and Dr Colin M Howles for valuable comments and suggestions on the manuscript.

DISCLOSURES

Conflict of interest: The authors declare no conflict of interest. Human rights statements and informed consent: All the procedures were followed in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the principles of the Helsinki Declaration of 1964 and its later amendments. This study was approved by the Institutional Review Board of Asada Ladies Clinic. This is a retrospective study in patients who submitted informed consent for undergoing fertility treatment at our IVF center. Animal studies: This article does not contain any study with animal participants that have been performed by any of the authors.

ORCID

Hiroya Kitasaka [https://orcid.org/0000-0001-5850-2773]
Noriyuki Fukunaga [https://orcid.org/0000-0003-2161-3319]
Yoshimasa Asada [https://orcid.org/0000-0002-0448-9953]

REFERENCES

1. Goldsman MP, Pedram A, Díazmerez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril. 1995;63(2):268-272.
2. Tolland A, Holst N, Forsdahl F, Fadnes HO, Oian P, Maltau JM. Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization. Am J Obstet Gynecol. 1990;162(2):554-558.
3. Gomez R, Soares SR, Busso C, García-Velasco JA, Simon C, Pellicer A. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med. 2010;28(6):448-457.
4. Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2008;90(5 Suppl):S188-S193.
5. McClure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. *Lancet*. 1994;344:235-236. https://doi.org/10.1016/S0140-6736(94)93001-5

6. Gomez R, Simon C, Remohi J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. *Biol Reprod*. 2003;68(6):2164-2171. https://doi.org/10.1095/biolreprod.102.010801

7. Wang TH, Horng SG, Chang CL, et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. *J Clin Endocrinol Metab*. 2002;87(7):3300-3308. https://doi.org/10.1210/jc.87.7.3300

8. Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. *Cochrane Database Syst Rev*. 2017;1(1):CD012103.

9. Budinetz TH, Mann JS, Griffin DW, Benadiva CA, Nulsen JC, Engmann LL. Maternal and neonatal outcomes after gonadotropin-releasing hormone agonist trigger for final oocyte maturation in patients undergoing in vitro fertilization. *Fertil Steril*. 2014;102(3):753-758.

10. Lainas TG, Spontouris IA, Zorozvillis IZ, et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). *Hum Reprod*. 2010;25(3):683-689.

11. Gilliam ML. Gonadotropin-releasing hormone antagonists for assisted reproductive technology. *Obstet Gynecol*. 2011;118(3):706-707.

12. Chen SL, Ye DS, Chen X, et al. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. *Hum Reprod*. 2012;27(5):1351-1356.

13. Kummer NE, Feinn RS, Griffin DW, Nulsen JC, Benadiva CA, Engmann LL. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger. *Hum Reprod*. 2013;28(1):152-159.

14. Shapiro BS, Daneshmand ST, Restrepo H, Garner FC, Aguierre M, Hudson C. Efficacy of induced luteinizing hormone surge after “trigger” with gonadotropin-releasing hormone agonist. *Fertil Steril*. 2011;95(2):826-828.

15. Meyer L, Murphy LA, Gumer A, Reichman DE, Rosenwaks Z, Cholst IN. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during *in vitro* fertilization cycles. *Fertil Steril*. 2015;104(3):637-642.

16. Castillo JC, Garcia-Velasco J, Humaidan P. Empty follicle syndrome after GnRHa triggering versus HCG triggering in COS. *J Assist Reprod Genet*. 2012;29(3):249-253.

17. Deepika K, Sindhuma D, Kiran B, Ravishankar N, Gautham P, Kamini R. Empty follicle syndrome following GnRHa trigger in PCOS patients undergoing IVF cycles. *J Reprod Infertil*. 2018;19(1):16-25.

18. Honnma H, Hashiba Y, Asada Y, Endo T. Failure of triggering oocyte maturation with a GnRH agonist in polycystic ovary syndrome: two case reports. *Eur J Obstet Gynecol Reprod Biol*. 2011;157(2):239-240.

19. Asada Y, Itoi F, Honnma H, et al. Failure of GnRHa agonist-triggered oocyte maturation: its cause and management. *J Assist Reprod Genet*. 2013;30(4):581-585.

20. Asada Y, Tokoro M, Sonohara M, Fukunaga N, Hattori Y, Hashiba Y. Long-term outcomes of freeze-all strategy: a retrospective analysis from a single ART center in Japan. *Reprod Med Biol*. 2019;18(2):173-179.

21. Abdelmassih S, Cardoso J, Abdelmassih V, Dias JA, Abdelmassih R, Nagy ZP. Laser-assisted ICSI: a novel approach to obtain higher oocyte survival and embryo quality rates. *Hum Reprod*. 2002;17(10):2694-2699.

22. Ebner T, Moser M, Sommergruber M, Jesacher K, Tews G. Complete oocyte activation failure after ICSI can be overcome by a modified injection technique. *Hum Reprod*. 2004;19(8):1837-1841.

23. De Vos A, Van Landuyt L, Van Ranst H, et al. Randomized sibling-oocyte study using recombinant human hyaluronidase versus bovine-derived Sigma hyaluronidase in ICSI patients. *Hum Reprod*. 2008;23(8):1815-1819.

24. Chang FE, Beall SA, Cox JM, Richter KS, DeCherney AH, Levy MJ. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response. *Fertil Steril*. 2016;106(5):1093-1100.e3.

25. Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. *Am J Pathol*. 1995;146(1):157-165.

26. Sugino N, Kashida S, Takiguchi S, Karube A, Kato H. Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy. *J Clin Endocrinol Metab*. 2000;85(10):3919-3924. https://doi.org/10.1210/jcem.85.10.6888

27. Otani N, Minami S, Yamato M, et al. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. *J Clin Endocrinol Metab*. 1999;84(10):3845-3851. https://doi.org/10.1210/jcem.84.10.6025

28. Chen D, Burmeister L, Goldschlag D, Rosenwaks Z. Ovarian hyperstimulation syndrome: strategies for prevention. *Reprod BioMed Online*. 2003;7:43-49.

29. Nargund G, Hutchison L, Scaramuzzi R, Campbell S. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. *Reprod BioMed Online*. 2007;14(6):682-685.

30. Gunvala V, Melnick A, Irani M, et al. Sliding scale HCG trigger yields equivalent pregnancy outcomes and reduces ovarian hyperstimulation syndrome: analysis of 10,427 IVF-ICSI cycles. *PLoS One*. 2017;12(4):e0176019. https://doi.org/10.1371/journal.pone.0176019

31. Esinler I, Bozdag G, Karakocskomsuener L. Preventing ovarian hyperstimulation syndrome: cabergoline versus coating. *Arch Gynecol Obstet*. 2013;288(5):1159-1163.

32. Leitao VM, Moroni RM, Seko LM, Nastrti CO, Martins WP. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. *Fertil Steril*. 2014;101(3):664-675.

33. Van Steirteghem AC, Nagy Z, Joris H, et al. High fertilization and implantation rates after intracytoplasmic sperm injection. *Hum Reprod*. 1993;8(7):1061-1066.

34. Nagy ZP, Liu J, Joris G, et al. The influence of the site of sperm deposition and mode of oolemma breakage at intracytoplasmic sperm injection on fertilization and embryo development rates. *Hum Reprod*. 1995;10(12):3171-3177.

35. Staessen C, Van Steirteghem AC. The chromosomal constitution of embryos developing from abnormally fertilized oocytes after intracytoplasmic sperm injection and conventional in vitro fertilization. *Hum Reprod*. 1997;12(2):321-327.

36. Macas E, Imthurn B, Rosselli M, Keller PJ. The chromosomal complements of multipronuclear human zygotes resulting from intracytoplasmic sperm injection. *Hum Reprod*. 1996;11(11):2496-2501.

37. Ono T, Mizutani E, Lin C, Yamagata K, Wakayama T. Offspring from intracytoplasmic sperm injection of aged mouse oocytes treated with caffeine or MG132. *Genesis*. 2011;49(6):460-471.

38. Wakayama S, Thuan NV, Kishigami S, et al. Production of offspring from one-day-old oocytes stored at room temperature. *J Reprod Dev*. 2004;50(6):627-637.

39. George MA, Pickering SJ, Braude PR, Johnson MH. The distribution of alpha- and gamma-tubulin in fresh and aged human
and mouse oocytes exposed to cryoprotectant. Mol Hum Reprod. 1996;2(6):445-456.

40. Wang WH, Meng L, Hackett RJ, Odenbourg R, Keefe DL. The spindle observation and its relationship with fertilization after intracytoplasmic sperm injection in living human oocytes. Fertil Steril. 2001;75(2):348-353.

41. Eichenlaub-Ritter U, Stahl A, Luciani JM. The microtubular cytoskeleton and chromosomes of unfertilized human oocytes aged in vitro. Hum Genet. 1988;80(3):259-264.

42. Zhang X, Liu X, Chen L, et al. Caffeine delays oocyte aging and maintains the quality of aged oocytes safely in mouse. Oncotarget. 2017;8(13):20602-20611.

43. Popovic-Todorovic B, Santos-Ribeiro S, Drakopoulos P, et al. Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation. Hum Reprod. 2019;34(10):2027-2035.

How to cite this article: Kitasaka H, Tokoro M, Kojima M, Fukunaga N, Asada Y. Gonadotropin levels at the start of ovarian stimulation predict normal fertilization after hCG re-trigger in GnRH antagonist cycles. Reprod Med Biol. 2021;20:96-107. https://doi.org/10.1002/rmb2.12359